Nirav Shah to Protein Kinase Inhibitors
This is a "connection" page, showing publications Nirav Shah has written about Protein Kinase Inhibitors.
Connection Strength
1.491
-
The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors. Clin Adv Hematol Oncol. 2024 Apr; 22(3):140-147.
Score: 0.683
-
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
Score: 0.174
-
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jul 06; 389(1):33-44.
Score: 0.162
-
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 08 20; 41(24):3988-3997.
Score: 0.161
-
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
Score: 0.138
-
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479.
Score: 0.134
-
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK?inhibitor in BTK?inhibitor?naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18(36):3961-3969.
Score: 0.039